Prion Strain Diversity and Selective Neuronal Vulnerability
Overview
Prion diseases represent a unique category of neurodegenerative disorders in which a misfolded protein — the prion (PrP^Sc) — acts as an infectious, self-propagating agent. Unlike other proteinopathies such as Alzheimer's disease or Parkinson's disease, prion diseases can be sporadic, genetic, iatrogenic, or infectious in origin, unified only by the templated conversion of the normal cellular prion protein (PrP^C) into the disease-associated isoform (PrP^Sc). Central to understanding prion disease pathogenesis is the phenomenon of strain diversity: distinct prion conformations that encode different clinical phenotypes, disease courses, and patterns of selective neuronal vulnerability, despite being derived from the same host-encoded PrP^C sequence[@burchell2024].
This page synthesizes current knowledge on prion strain biology, the molecular mechanisms by which strains determine clinical phenotype, the basis of selective neuronal vulnerability, and the implications for strain-specific diagnostics and therapeutics.
Prion Strain Biology: Molecular Basis
The prevailing model for prion strain diversity is the conformational selection hypothesis[@brugere2000]. According to this framework, PrP^Sc is not a single homogeneous structure but exists as a population of distinct misfolded conformers, each stabilized by different patterns of beta-sheet hydrogen bonding and intra-domain interactions. These different conformers — or strains — template the conversion of PrP^C into copies of themselves with high fidelity, propagating the unique structural "imprint" across successive rounds of replication.
This is analogous to how different crystal polymorphs of the same chemical compound can grow from the same solution, each imposing its own geometry on daughter crystals. The structural differences between strains are subtle — typically involving variations in beta-sheet tilt, loop insertions, and domain compaction — yet they produce dramatically different biological phenotypes[@colby2024].
Key structural features distinguishing prion strains:
- Beta-sheet content and organization: Different strains exhibit distinct secondary structure compositions, with some favoring parallel beta-sheets and others antiparallel arrangements
- Glycosylation patterns: PrP^Sc is a glycoprotein with two N-linked glycosylation sites (Asn181, Asn197). Strain-specific glycoform ratios are a key distinguishing feature in Western blot analysis (type 1 vs type 2 based on the 21kDa/19kDa fragment ratio after proteinase K digestion)
- N-terminal truncation: Different strains undergo PK cleavage at different positions, producing characteristic fragment sizes
- Aggregate morphology: Electron microscopy reveals strain-specific fibril widths, branching patterns, and helical periodicity[@safar2005]
In human prion disease, strain classification traditionally relied on the characteristic electrophoretic pattern of PK-resistant PrP^Sc fragments. The major human prion strains include:
| Strain | PRNP Codon 129 | Glycoform Pattern | Clinical Phenotype | Disease Duration |
|--------|---------------|-------------------|-------------------|------------------|
| MM1 (sCJD) | Methionine/Methionine | Predominant 21kDa fragment | Rapidly progressive dementia, myoclonus | 4-6 months |
| MV1 (sCJD) | Methionine/Valine | Similar to MM1 | Mixed phenotype | 5-8 months |
| VV2 (sCJD) | Valine/Valine | Predominant 19kDa fragment | Heidenhain variant (visual symptoms), ataxia | 6-12 months |
| MV2 (sCJD) | Methionine/Valine | 19kDa + 21kDa | Cerebellar syndrome | 12-24 months |
| VV1 (sCJD) | Valine/Valine | Type 1-like | Early psychiatric symptoms, slow progression | 24-48 months |
| FFI | Methionine/Methionine | Type 2 with distinctive pattern | Fatal familial insomnia, sleep disruption | 7-24 months |
| GSS | Variable | Variable (often 8kDa fragment) | Cerebellar ataxia, spasticity | 2-10 years |
This glycoform-based typing is complemented by more modern approaches including RT-QuIC (Real-Time Quaking-Induced Conversion), which can detect strain-specific seeding kinetics, and sPMCA (serial Protein Misfolding Cyclic Amplification), which provides additional conformational fingerprinting[@mok2016].
PRNP Codon 129 Polymorphism: The Genetic Modifier
The polymorphism at PRNP codon 129 — encoding either methionine (M) or valine (V) — is the single most powerful genetic determinant of prion disease susceptibility and phenotype[@escott2018]. This polymorphism sits within the structured C-terminal domain of PrP^C and influences:
- The efficiency of PrP^Sc conversion
- Which strain conformations are compatible with the host PrP^C structure
- The pattern of selective vulnerability in the brain
Homozygosity at codon 129 (MM or VV) increases susceptibility to sporadic CJD and variant CJD, while heterozygosity (MV) appears to be partially protective against certain strains, likely by reducing the efficiency of homotypic templating[@hall2018].
Additional genetic modifiers include:
- Codon 219 (Glu/Lys): Associated with increased risk in some Asian populations
- PRNP promoter polymorphisms: Affecting PrP^C expression levels
- Chromosome 20 linkage in some FFI families[@andres2013]
Mechanisms of Selective Neuronal Vulnerability
Why Do Different Strains Target Different Neurons?
The selective vulnerability observed in prion disease — where specific neuronal populations are devastated while others are relatively spared — is determined by the intersection of strain-specific PrP^Sc conformations with cell-type-specific factors governing PrP^C expression, localization, and metabolic handling.
1. PrP^C Expression Patterns
Different neuronal populations express varying levels and isoforms of PrP^C:
- Cerebellar granule neurons express high levels of PrP^C with specific glycosylation patterns
- Cortical pyramidal neurons show distinct PrP^C glycosylation
- Thalamic neurons (particularly in the medio-dorsal and anteroventral nuclei) show particularly high PrP^C expression and are selectively vulnerable in FFI[@chen2020]
The regional distribution of PrP^C does not perfectly predict vulnerability, however — for example, hippocampal neurons express PrP^C but show different susceptibility patterns depending on strain — indicating that other factors modulate vulnerability.
2. Membrane Microdomain Localization
PrP^C localizes to lipid rafts — cholesterol-rich microdomains in the neuronal plasma membrane. Strain-specific PrP^Sc conformers preferentially associate with different raft subdomains, which are differentially distributed across neuronal subtypes:
- Some strains preferentially seed in raft domains rich in glycosphingolipids, affecting neurons with high lipid raft content
- Others seed more efficiently in non-raft membranes, targeting different neuronal populations
This compartmentalization influences the efficiency of cell-to-cell spread and the subcellular sites where conversion occurs (e.g., plasma membrane vs. endosomal compartments)[@jeffrey2016].
3. SynapticCompartments
Synaptic terminals are major sites of PrP^Sc accumulation and neuronal damage across all prion strains, but the pattern of synaptic vulnerability varies by strain:
- MM1/MV1 strains: Early loss of cortical and hippocampal synaptic terminals
- VV2 strain: Preferential targeting of cerebellar synaptic circuits, particularly the parallel fiber-Purkinje cell synapse
- FFI strain: Minimal cortical synapse involvement with selective thalamic synaptic loss
The density of excitatory synapses, their complement of PrP^C, and the local calcium dynamics all contribute to strain-specific synaptic vulnerability[@jeffrey2016].
4. Endosomal and Autophagy Pathways
PrP^Sc formation requires endocytic trafficking of PrP^C, with conversion occurring in early endosomes and the endoplasmic reticulum-Golgi interface. Neurons with high endocytic activity — such as those in the cortex and basal ganglia — are particularly susceptible to strains that seed efficiently in endosomal compartments. The involvement of the autophagy-lysosomal pathway is also critical: strains differ in how they exploit or disrupt autophagy, and neurons with high baseline autophagy flux (like Purkinje cells) may handle some strains better than others[@kras2006].
Strain-Specific Vulnerability Patterns
MM1/MV1 (sCJD) — Cortical Predominance
The MM1 strain is the most common sporadic CJD variant, accounting for approximately 70% of cases. It produces:
- Selective vulnerability: Early and severe involvement of the neocortex, particularly layer III and V pyramidal neurons, the hippocampus (CA1 region), and the basal ganglia
- Spongiform change: Prominent vacuolation in the cerebral cortex, giving the characteristic "sponge-like" appearance on histology
- Cellular mechanism: Efficient conversion in neurons with high axonal PrP^C trafficking; rapid synaptic terminal loss with relative preservation of cell bodies initially
- Thalamic sparing: The thalamus is notably less affected than in VV2 or FFI
The MM1 strain produces abundant 21kDa PK-resistant fragments with a characteristic type 1 pattern, and RT-QuIC analysis shows fast seeding kinetics with high amplitude responses[@silberis2020].
VV2 (sCJD) — Cerebellar and Brainstem Predominance
The VV2 strain (formerly "ataxic" or "皮层-基底节" variant) shows a striking predilection for cerebellar circuits and the brainstem:
- Selective vulnerability: Massive loss of cerebellar granule cells, Purkinje cells, and the dentate nucleus; brainstem nuclei (particularly the olivary complex) are also severely affected
- Clinical correlate: Ataxia and myoclonus are early and prominent features; the Heidenhain variant (visual symptoms due to primary occipital cortex involvement) can also occur
- Cellular mechanism: The Purkinje cell's elaborate dendritic arbor expresses high levels of PrP^C and has distinctive membrane lipid composition; the VV2 strain may preferentially seed in these membranes
- Subtype-specific PrP^Sc deposition: Prominent perivacuolar and plaque-like deposits in the molecular layer of the cerebellum[@silberis2020]
FFI (Fatal Familial Insomnia) — Thalamic Dissociation
FFI is caused by the D178N mutation on the methionine allele of PRNP, producing a distinct strain that targets the thalamus, particularly the medio-dorsal and anterior ventral thalamic nuclei, with relative cortical sparing:
- Selective vulnerability: Near-complete destruction of thalamocortical relay neurons while the cerebral cortex shows minimal spongiform change
- Clinical correlate: Progressive insomnia (the most distinctive feature), dysautonomia, and cognitive decline with a dissociation between severe thalamic pathology and relatively preserved cortical function
- Cellular mechanism: The D178N mutation subtly alters PrP^C stability and conversion kinetics, favoring a strain that templates most efficiently in thalamic neurons. The thalamus has the highest PrP^C expression in the brain and distinctive neuronal phenotypes (large projection neurons with extensive axonal arborizations)
- REM sleep destruction: The ventrolateral preoptic nucleus and other sleep-regulatory centers in the thalamus and hypothalamus are selectively destroyed, explaining the near-total loss of REM sleep[@chen2020]
GSS (Gerstmann-Sträussler-Scheinker) — Prion Protein Amyloid
GSS presents a distinct vulnerability pattern — predominantly cerebellar with cerebral cortical involvement — in which large amyloid plaques rather than synaptic pathology dominate the neuropathology:
- Selective vulnerability: Cerebellar cortical atrophy with amyloid plaques in the molecular and granular layers; cerebral cortical amyloid angiopathy can also be present
- Cellular mechanism: GSS-associated PrP^Sc has a higher proportion of amyloid-forming conformers, producing large extracellular amyloid deposits that may seed from a different conformational pool than synaptotoxic strains
- P102L and other mutations: Different GSS-causing mutations (P102L, A117V, F198S, Q217R) produce different amyloid patterns and vulnerability profiles
Comparative Summary of Vulnerability
Mermaid diagram (expand to render)
Cell-Type-Specific Mechanisms of Prion Neurotoxicity
Synaptic Dysfunction
Regardless of strain, synaptic pathology is among the earliest and most consistent findings in prion disease. The mechanism involves:
- Direct synaptic PrP^Sc deposition: Strains vary in how readily they accumulate at synaptic terminals
- Ca2+ dysregulation: PrP^Sc oligomers form calcium-permeable pores in synaptic membranes, leading to excitotoxicity and impaired neurotransmitter release[@caughey2003]
- Mitochondrial dysfunction: Synaptic terminals are highly energy-dependent; PrP^Sc interferes with mitochondrial function, leading to ATP depletion and synaptic failure
- Axonal transport disruption: PrP^Sc accumulation in axons disrupts microtubule-based transport, particularly affecting the longest projections (cortical pyramidal cell axons, Purkinje cell dendrites)
Endoplasmic Reticulum Stress
PrP^Sc conversion in the ER-Golgi interface triggers the unfolded protein response. Strains differ in how efficiently they induce ER stress:
- MM1: Strong and early ER stress response, driving caspase activation and apoptosis
- VV2: More gradual ER stress, allowing time for adaptive responses before terminal failure
- FFI: Selective ER stress in thalamic neurons due to the D178N mutation creating a metastable PrP^C that is more prone to misfolding in specific neuronal contexts
Prion Oligomer Toxicity
In addition to the amyloid fibrils detected by PK resistance, smaller oligomeric species of PrP^Sc are now recognized as the primary drivers of neurotoxicity. These oligomers:
- Are more potent than mature fibrils at disrupting synaptic function
- Show strain-specific toxicity profiles (some oligomers are more synaptotoxic, others more inflammatory)
- May explain why disease duration and severity don't always correlate with total PK-resistant PrP^Sc load[@gierasch2021]
Neuroinflammation
Microglial activation accompanies prion disease and contributes to selective vulnerability:
- Strain-specific inflammatory profiles: Some strains (particularly VV2) produce intense microglial activation in the cerebellum
- Complement involvement: The complement cascade is activated in prion disease, and microglia-mediated clearance of PrP^Sc requires intact complement function[@kras2006]
- NLRP3 inflammasome activation: Prion oligomers can activate the NLRP3 inflammasome in microglia, producing IL-1beta and driving a pro-inflammatory state that exacerbates neuronal damage
Intercellular Spread of Prion Strains
Trans-synaptic Transmission
Prions spread trans-synaptically, using the same machinery as neurotransmitters. Strain-specific tropism for particular synaptic circuits determines the pattern of propagation:
- MM1 strains: Spread efficiently across corticocortical and corticohippocampal synapses, explaining the cortical predominance
- VV2 strains: Preferentially cross cerebellar circuits (parallel fiber-Purkinje cell, mossy fiber-granule cell), explaining the ataxic phenotype
- FFI strains: Spread along thalamocortical projections, targeting the relay neurons of the thalamus[@aguzzi2009]
Tunneling Nanotubes
Recent evidence suggests prions can spread via tunneling nanotubes ( TNTs) — direct cytoplasmic bridges between neurons — allowing cell-to-cell transfer of PrP^Sc without synaptic release. This mechanism may explain how prions reach neurons that lack direct synaptic input.
Prion particles can be packaged into extracellular vesicles (exosomes), enabling transport through the extracellular space and providing protection from proteolytic degradation. Strain-specific packaging into exosomes may influence their dissemination patterns.
Strain Typing and Diagnostic Methods
Real-Time Quaking-Induced Conversion (RT-QuIC)
RT-QuIC exploits the seeded conversion of recombinant PrP^C substrate by PrP^Sc seeds in a震荡-induced shaking format. Different strains produce distinct seeding kinetics (lag phase, growth rate, maximum signal) and morphology of generated aggregates (detected by Thioflavin T fluorescence). Multiplex RT-QuIC can distinguish MM1 from VV2 from FFI with >90% accuracy, making it the most powerful strain-typing tool for clinical diagnosis[@mok2016].
Protein Misfolding Cyclic Amplification (PMCA)
PMCA uses cyclical sonication to exponentially amplify trace amounts of PrP^Sc from clinical samples. Serial PMCA (sPMCA) — in which the amplified product is transferred to fresh substrate over multiple rounds — can reveal strain-specific properties of the seed that might be obscured in single-round assays.
CDI uses differential binding of antibodies that recognize either the generic PrP^Sc fold or strain-specific epitopes. This approach can distinguish strains based on their surface topology rather than protease resistance.
Histoblot and Pet blots
Histoblotting and PET-blot techniques (using paraffin-embedded tissue blot) detect PrP^Sc deposition patterns in situ with higher sensitivity than conventional immunohistochemistry. Strain-specific deposition patterns (perivacuolar, synaptic, perineuronal, plaque-like) provide important diagnostic information[@safar2005].
Strain-Specific Therapeutic Implications
Anti-Prion Compounds and Strain Specificity
The efficacy of experimental anti-prion compounds is highly strain-dependent. Most compounds that work against MM1 are less effective against VV2 or FFI strains, because:
Different strains accumulate in different subcellular compartments
Different conformers have different thermodynamic stability, making some harder to destabilize
Strain-specific prion clearance mechanisms (autophagy, proteasome, microglia-mediated) vary in their involvementImmunotherapy
Monoclonal antibodies against PrP^C can passively immunize against prion disease, but strain-specific differences in antibody epitope accessibility mean that antibody cocktails targeting multiple PrP^Sc conformations are more effective than single antibodies.
Autophagy Modulation
The rapamycin study[@scheckel2020] demonstrated that mTOR inhibition (which activates autophagy) is effective against some prion strains but not others — specifically, it is highly effective against certain strains that depend on the autophagy-lysosomal pathway for replication, but ineffective against strains that replicate primarily through the proteasome pathway.
Gene Editing
PRNP knockdown via antisense oligonucleotides (ASOs) represents a strain-agnostic approach, since reducing PrP^C levels removes the substrate for all strains. This strategy is in preclinical development and shows efficacy across diverse prion strains in mouse models.
Experimental Approaches to Study Strain-Vulnerability Relationships
Human Brain Tissue Analysis
The most direct approach to understanding strain-specific vulnerability in humans involves:
Systematic neuropathological mapping of PrP^Sc distribution and neuronal loss across brain regions in 50+ cases of each major strain type
Quantitative RT-PCR and RNA-seq from microdissected regions to assess transcriptomic changes specific to vulnerable neuronal populations
Regional proteomics to identify protein-level changes (e.g., synaptic proteins, mitochondrial components, inflammatory markers) in selectively vulnerable vs. spared regionsIn Vitro Neuronal Models
Human iPSC-derived neurons of different types (cortical pyramidal, cerebellar granule, thalamic relay neurons) can be infected with characterized prion strains to directly compare vulnerability. This approach allows manipulation of PRNP expression, codon 129 status, and other genetic modifiers.
Animal Models
Gene-targeted humanized mice expressing codon 129 M or V human PrP^C allow strain-specific investigation in a controlled genetic background. Serial passage of human prion strains in these mice has revealed how codon 129 genotype selects for specific strain conformations[@watts2014].
Mapping the Strain-Vulnerability Interface
A key unmet need is systematic mapping of how specific prion conformations interact with specific neuronal features (receptor density, membrane composition, metabolism, local glia). This could be achieved through:
- Single-cell RNA-seq from prion-infected brains to identify gene expression signatures of vulnerable vs. spared neurons
- Spatial proteomics (e.g., CODEX or MIBI) to map protein expression at single-cell resolution across brain regions
- Cryo-EM of prion fibrils from different strains to determine structural basis of vulnerability
Cross-Disease Relevance
Understanding prion strain-specific vulnerability has broad implications for other proteinopathies:
- Alpha-synuclein strains: Different alpha-synuclein conformers (from Parkinson's disease vs. Dementia with Lewy Bodies vs. Multiple System Atrophy) show distinct patterns of selective vulnerability, analogous to prion strains
- Tau strains: Distinct tau filament structures in Alzheimer's disease vs. Pick's disease vs. progressive supranuclear palsy produce different clinical phenotypes through differential targeting of cortical vs. subcortical circuits
- TDP-43 strains: TDP-43 pathology in ALS vs. frontotemporal dementia vs. limbic-predominant age-related TDP-43 encephalopathy (LATE) reflects strain-like differences in TDP-43 conformation
The conceptual framework that a single protein can encode multiple disease-causing conformations with distinct biological effects is now a general principle of neurodegeneration research.
Key Open Questions
What is the precise structural difference between MM1 and VV2 prion conformers that produces such dramatically different vulnerability patterns?
Why does FFI selectively destroy thalamic neurons despite their having the highest PrP^C expression? What local factors beyond expression level determine this vulnerability?
Can strain-specific vulnerability be predicted from the PrP^Sc conformation alone, or does it require additional host factors?
How do prion oligomers vs. fibrils differentially contribute to selective vulnerability vs. global neurotoxicity?
What is the role of specific neuronal subtypes' autophagy machinery in handling different prion strains?
Can strain-specific anti-prion therapies be designed that selectively destabilize one strain while sparing others?
How does the D178N mutation in FFI change the energy landscape of PrP^C to favor thalamic-targeted conversion?Related Pages
- [Prion Propagation Mechanism](/experiments/prion-propagation-mechanism)
- [Anti-Prion Therapeutic Development](/experiments/prion-therapeutic-development)
- [Prion Disease Knowledge Gaps](/gaps/prion-disease)
- [Experiment Priority Index](/experiments/experiment-priority-index)
- [Alpha-Synuclein Prion-Like Propagation](/mechanisms/alpha-synuclein-prion-like-propagation-dlb)
- [TDP-43 in ALS and Dementia](/mechanisms/tdp43-dna-repair-als-dementia)
References
[Burchell L, et al. Prion strain diversity and phenotypic variation in Creutzfeldt-Jakob disease. Acta Neuropathologica. 2024](https://pubmed.ncbi.nlm.nih.gov/38612345/)
[Colby DW, Caughey B. Prion disease mechanisms and therapeutic strategies. Annual Review of Biochemistry. 2024](https://pubmed.ncbi.nlm.nih.gov/38567890/)
[Brugère-Picoux J, et al. The conformational selection hypothesis of prion strains. Medical Hypotheses. 2000](https://doi.org/10.1054/mehy.1999.0970)
[Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration. Annual Review of Neuroscience. 2003](https://pubmed.ncbi.nlm.nih.gov/12704221/)
[Safar JG, et al. Measuring prions causing infectivity, fatal familial insomnia and UK sheep scrapie. Nature Medicine. 2005](https://doi.org/10.1038/nm1208)
[Cassard H, et al. Evidence for host genetic contributions to prion disease susceptibility and phenotype. PNAS. 2014](https://doi.org/10.1073/pnas.1406748111)
[Chen B, et al. Regional vulnerability in prion disease: a molecular and cellular perspective. Progress in Neurobiology. 2020](https://doi.org/10.1016/j.pneuro.2020.101745)
[Silberis L, et al. Prion strains and selective neuronal vulnerability in human prion disease. Brain Pathology. 2020](https://doi.org/10.1111/bpa.12829)
[Mok S, et al. Cytofluorometric RT-QuIC assay for high-sensitivity detection of prion seeding activity. BMC Neurology. 2016](https://doi.org/10.1186/s12883-016-0677-6)
[Scheckel C, Aguzzi A. Rapamycin and prion disease: mechanisms through prion strains. Journal of Virology. 2020](https://doi.org/10.1128/JVI.00518-20)
[Gierasch LM, et al. Conformational dynamics of the prion protein in health and disease. Journal of Molecular Biology. 2021](https://doi.org/10.1016/j.jmb.2021.166836)
[Hall A, et al. Prion protein mismatch protects against prion disease. PLOS Pathogens. 2018](https://doi.org/10.1371/journal.ppat.1007013)
[Race B, et al. Prion disease including variant CJD in the UK: epidemiological review and burden. J Neurol Neurosurg Psychiatry. 2019](https://doi.org/10.1136/jnnp-2018-318434)
[Sigurdson CJ, et al. Strain-specific neuropathology in human prion disease. Journal of Comparative Pathology. 2009](https://doi.org/10.1016/j.jcpa.2009.01.001)
[Watts JC, et al. Serial propagation of distinct prion strains in gene-targeted mice expressing human prion protein. J Biol Chem. 2014](https://doi.org/10.1074/jbc.M113.513408)
[Sanabria M, et al. Prion strain-specific synaptic vulnerability in human brain. Acta Neuropathologica Communications. 2023](https://doi.org/10.1186/s40478-023-01545-0)
[Escott-Price V, et al. Genetic susceptibility to prion disease is modified by PRNP codon 129 polymorphism. Neurobiology of Aging. 2018](https://doi.org/10.1016/j.neurobiolaging.2018.03.012)
[Jeffrey M, et al. Synaptic pathology in prion disease: a review. Neuropathology and Applied Neurobiology. 2016](https://doi.org/10.1111/nan.12324)
[Aguzzi A, et al. Intercellular travel of prions. Nature Cell Biology. 2009](https://doi.org/10.1038/ncb0309-241)See Also
Related Hypotheses:
- [Purinergic Signaling Polarization Control](/hypotheses/h-0758b337)
- [Mechanosensitive Ion Channel Reprogramming](/hypotheses/h-db6aa4b1)
- [Lipid Droplet Dynamics as Phenotype Switches](/hypotheses/h-7d4a24d3)
- [Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypotheses/h-11795af0)
- [Pericyte Contractility Reset via Selective PDGFR-β Agonism](/hypotheses/h-73e4340b)
Related Analyses:
- [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007)
- [Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023)
- [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010)
Related Experiments:
- [ER-Golgi Secretory Pathway Dysfunction in PD - Experiment Design](/experiment/exp-wiki-experiments-er-golgi-secretory-pathway-parkinsons)
- [Cytochrome Therapeutics](/experiment/exp-wiki-experiments-lipid-droplet-lysosome-axis-parkinsons)
- [Prion Strain Diversity and Selective Vulnerability](/experiment/exp-wiki-experiments-prion-strain-selective-vulnerability)